0QF:FRA
Moderna Inc
181,66 €
arrow_upward
+0,91%(+1,64) 1D
30. ruj, 08:43:20 GMT+2 · EUR
search
Svi simboli
1D
5D
1M
6M
GDD
1G
5G
MAKS
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 0QF...
Otvori
181,30 €
Najviša
181,66 €
Najniža
181,30 €
Trž. kap.
81,23 mlr.
Prosj. kol.
4,02 tis.
Količina
244,00
52-tjed. najviša
181,66 €
52-tjed. najniža
19,26 €
Broj djelatnika
5 tis.
Otvori
181,30 €
Najviša
181,66 €
Najniža
181,30 €
Trž. kap.
81,23 mlr.
Prosj. kol.
4,02 tis.
Količina
244,00
52-tjed. najviša
181,66 €
52-tjed. najniža
19,26 €
Broj djelatnika
5 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
AD HOC NEWS
·
prije 37 minuta
Moderna stock pre-market at EUR 181.09: plus 1.46 percent
Investing.com Nigeria
·
prije 17 sati
Moderna stock hits 52-week high at 202.69 USD By Investing.com
The Globe and Mail
·
prije 1 dan
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?
Yahoo Finance
·
prije 1 dan
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
Profil
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In 2026, Time ranked Moderna as number one in their World's Most Impactful Companies list. Wikipedia
Moderna Inc – informacije
Glavni izvršni direktorStéphane Bancel
Zaposlenici4,7 tis.
Osnovanoruj 2010
Sjedište-
Sektor-
Web-lokacijamodernatx.com